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The transformative discoveries in the field of genetics have
led to a revolution in the way that diseases of genetic
origin can be studied and treated. The ability to profile a
patient’s genome to uncover all of the genetic variants at
once now provides physicians the opportunity to better
understand each patient’s disease and provides scientists a
new window into pathogenesis. The translation of ‘next
generation’ sequencing directly to the clinic is still being
assessed, but holds great promise for genetic disease to
reduce costs, advance accuracy, and point to unsuspected
and treatable conditions. To study its capability in the
clinic, we performed whole exome sequencing (WES) in
118 probands with a diagnosis of a pediatric-onset neuro-
developmental disease in which most known causes had
been excluded. Among several novel genes identified in
this study were EXOC8 in Joubert syndrome and GFM2
in microcephaly, simplified gyral pattern, and insulin-
dependent diabetes, further establishing WES as a useful
tool for novel gene discovery. Importantly, exome sequen-
cing uncovered 10 probands with mutations in genes
known to cause a disease different from the initial diagno-
sis. Upon further medical evaluation, these mutations were
found to account for each proband’s disease, leading to a
change in diagnosis, some of which led to changes in man-
agement. This data provide proof-of-principle that geno-
mic strategies are useful in reclassifying diagnosis in a
substantial proportion of patients. In order to explore
potential treatments for ciliopathy disorders, we devised a
cell-based screen, using a pharmacologically-relevant
RNAi library to search for genes modulating ciliogenesis
and cilia stability. Among the hits were several genes in
the actin regulatory network. We found that genes that
promote actin stability led to an inhibition of ciliogenesis,
whereas genes that inhibit actin stability promoted
ciliogenesis. Cytochalasin, a drug with potent actin inhibi-
tory activity, promoted ciliogenesis both in wildtype cells
as well as cells with mutations in key ciliogenesis gene.
While cytochalasin itself might be too toxic for human
use, these findings suggest pharmacological approaches to
treating ciliopathies. We have extended these findings by
probing the connection between ciliogenesis and the cell
cycle and have uncovered a node centered around HNF4,
encoding Hepatocyte nuclear factor 4, as a module linking
these two cellular stages. We are interested in optimizing
high-content cell-based screening strategies to identify
functional genetic requirements for a host of important
cell biological questions in the field of cilia in development
and disease.
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